Cargando…

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boudadi, Karim, Antonarakis, Emmanuel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798019/ https://www.ncbi.nlm.nih.gov/pubmed/27013902 http://dx.doi.org/10.4137/CMO.Ss34534

Ejemplares similares

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis
por: Mariano, Renato, et al.
Publicado: (2022)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial
por: Qin, Xiaojian, et al.
Publicado: (2022)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
por: Huhtaniemi, Riikka, et al.
Publicado: (2022)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
por: Pinto, Francesco, et al.
Publicado: (2022)

Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens()()
por: Nunes, Jessica J., et al.
Publicado: (2017)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Role of prostate cancer stem-like cells in the development of antiandrogen resistance
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
por: Hatano, Koji, et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_00ojj0qjvk1pnprc553k6qo64g